Readministration of Platinum Agents in Recurrent Ovarian Cancer Patients Who Developed Hypersensitivity Reactions to Carboplatin

Background/Aim: Hypersensitivity reactions (HSRs) to carboplatin, a key drug for ovarian cancer patients, are problematic. The aim of this study was to evaluate the efficacy and safety of readministration of platinum agents (PTs) in recurrent ovarian cancer patients who developed HSRs to carboplatin. Patients and Methods: Thirty-one patients with recurrent ovarian cancer who developed HSRs to carboplatin were divided into those who continued to receive PTs in the following cycle (continuation group, n=24) and those in whom either the drug was switched to non-platinum agents (non-PTs) or chemotherapy was ended (discontinuation group, n=7). Outcomes were evaluated based on patients' medical records. Results: The median survival time following HSRs was 28.1 and 15.4 months in the continuation and discontinuation groups, respectively (p=0.018). In the continuation group, a total of 155 cycles of PTs were re-administrated, and 50 cycles (32%) led to recurrent HSRs. There were no recurrent HSRs with a severity of grade 3 or greater. Conclusion: Continuation of PTs in ovarian cancer patients may contribute to improvement in their overall survival without severe recurrent HSRs.

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  D. Cohn,et al.  Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions. , 2019, Gynecologic oncology.

[3]  T. Sun,et al.  A cohort study of hypersensitivity reaction in patients with epithelial ovarian cancer treated with carboplatin , 2018, International Journal of Gynecologic Cancer.

[4]  Gloria S. Huang,et al.  Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer , 2018, Journal of Cancer Research and Clinical Oncology.

[5]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[6]  E. Ratner,et al.  Platinum desensitization in patients with carboplatin hypersensitivity: A single-institution retrospective study. , 2017, Gynecologic oncology.

[7]  A. Banerji,et al.  Skin Testing in the Evaluation and Management of Carboplatin-Related Hypersensitivity Reactions. , 2015, The journal of allergy and clinical immunology. In practice.

[8]  J. Berek,et al.  International Journal of Gynecology and Obstetrics Cancer of the Ovary, Fallopian Tube, and Peritoneum , 2022 .

[9]  H. Yoshikawa,et al.  Safety and efficacy of substituting nedaplatin after carboplatin hypersensitivity reactions in gynecologic malignancies , 2013, The journal of obstetrics and gynaecology research.

[10]  A. Iasonos,et al.  The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. , 2010, Gynecologic oncology.

[11]  D. Alberts,et al.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Miyagi,et al.  Incidence of Carboplatin-Related Hypersensitivity Reactions in Japanese Patients With Gynecologic Malignancies , 2009, International Journal of Gynecologic Cancer.

[13]  A. Jazaeri,et al.  Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. , 2007, American journal of obstetrics and gynecology.

[14]  K. Nozaki,et al.  Carboplatin hypersensitivity induced by low‐dose paclitaxel/carboplatin in multiple platinum‐treated patients with recurrent ovarian cancer , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[15]  Robert S Mannel,et al.  Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Sabbatini,et al.  Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. , 2002, Gynecologic oncology.

[17]  P. Sfikakis,et al.  Hypersensitivity Reactions to Carboplatin Administration Are Common but Not Always Severe: A 10-Year Experience , 2001, Oncology.

[18]  P. Elson,et al.  Clinical features of hypersensitivity reactions to carboplatin. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Kim,et al.  Life-threatening carboplatin hypersensitivity during conditioning for autologous PBSC transplantation: successful rechallenge after desensitization , 1998, Bone Marrow Transplantation.